Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US6686353B1 · kind B1 · utility
14Cited by
3References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 15, 1999 |
| Grant date | Feb 3, 2004 |
| Priority date | — |
| Expiry date | Jul 15, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells, and are useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.